Genzyme Corporation's Pompe Drug Rejected--New Production Woes
Reuters -- Genzyme Corp (GENZ.O), which is struggling through the most trying period in its history, said on Monday U.S. regulators will not approve its drug to treat Pompe disease, a rare muscle disorder, until it addresses manufacturing deficiencies at its Allston Landing plant in Boston.